Compare OGE & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OGE | NUVL |
|---|---|---|
| Founded | 1902 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 8.3B |
| IPO Year | 2009 | 2021 |
| Metric | OGE | NUVL |
|---|---|---|
| Price | $47.57 | $107.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 16 |
| Target Price | $48.11 | ★ $134.75 |
| AVG Volume (30 Days) | ★ 1.3M | 569.1K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | ★ 5.94 | N/A |
| EPS | ★ 2.32 | N/A |
| Revenue | ★ $3,260,100,000.00 | N/A |
| Revenue This Year | $3.74 | N/A |
| Revenue Next Year | $1.42 | $1,239.49 |
| P/E Ratio | $19.81 | ★ N/A |
| Revenue Growth | ★ 9.21 | N/A |
| 52 Week Low | $41.70 | $63.56 |
| 52 Week High | $50.13 | $113.02 |
| Indicator | OGE | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 47.67 | 59.94 |
| Support Level | $46.36 | $100.98 |
| Resistance Level | $49.16 | $112.61 |
| Average True Range (ATR) | 0.89 | 3.37 |
| MACD | -0.29 | 0.49 |
| Stochastic Oscillator | 40.98 | 81.32 |
OGE Energy is a holding company for Oklahoma Gas & Electric, a regulated utility with electricity generation, transmission, and distribution service for 900,000 customers in Oklahoma and western Arkansas. In December 2021, OGE divested its 25.5% stake in Enable Midstream Partners, an oil and gas services company it created in 2013 through a unit exchange merger with Energy Transfer. OGE sold its 95.4 million limited partner units of Energy Transfer throughout 2022. OGE sold its retail gas business in 1928 and no longer has any gas operations.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.